Joseph Palumbo
Chief Tech/Sci/R&D Officer chez BIOVIE INC.
Fortune : 3 930 $ au 31/03/2024
Profil
Joseph M.
Palumbo is currently the Director at Hydreight Technologies, Inc. and the Chief Medical Officer at BioVie, Inc. He previously worked as the Head-Global & Franchise Medical at Johnson & Johnson, Vice President-US Medical Science at Mitsubishi Tanabe Pharma Corp., and as the Chief Medical Officer & Vice President at Zynerba Pharmaceuticals, Inc. Palumbo holds an undergraduate degree from the University of Pennsylvania Graduate School of Education and a doctorate from George Washington University School of Medicine & Health.
Détentions connues dans des sociétés publiques
| Société | Date | Nombre d'actions | Valorisation | Date de valorisation |
|---|---|---|---|---|
BIOVIE INC. CLASS A
0,01% | 09/08/2023 | 7 430 ( 0,01% ) | 3 930 $ | 31/03/2024 |
Postes actifs de Joseph Palumbo
| Sociétés | Poste | Début |
|---|---|---|
| BIOVIE INC. | Chief Tech/Sci/R&D Officer | 01/11/2021 |
| HYDREIGHT TECHNOLOGIES INC. | Director/Board Member | 25/11/2022 |
Anciens postes connus de Joseph Palumbo
| Sociétés | Poste | Fin |
|---|---|---|
| ZYNERBA PHARMACEUTICALS, INC. | Chief Tech/Sci/R&D Officer | 01/10/2021 |
| JOHNSON & JOHNSON | Corporate Officer/Principal | - |
| MITSUBISHI TANABE PHARMA CORPORATION | Corporate Officer/Principal | - |
Formation de Joseph Palumbo
| University of Pennsylvania Graduate School of Education | Undergraduate Degree |
| George Washington University School of Medicine & Health | Doctorate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 4 |
|---|---|
| JOHNSON & JOHNSON | Health Technology |
| ZYNERBA PHARMACEUTICALS, INC. | Health Technology |
| BIOVIE INC. | Health Technology |
| HYDREIGHT TECHNOLOGIES INC. | Retail Trade |
| Entreprise privées | 1 |
|---|---|
Mitsubishi Tanabe Pharma Corp.
 Mitsubishi Tanabe Pharma Corp. Pharmaceuticals: OtherHealth Technology Mitsubishi Tanabe Pharma Corp. engages in the research, development, manufacture, and sale of pharmaceutical products. Its products include Remicade, Ceredist, Talion, Kremezin, Maintate, Simponi, Lexapro, Tenelia, Tetrabik, and Imusera. The company was founded by Gohei Tanabeya in 1678 and is headquartered in Osaka, Japan. | Health Technology |
